Login to Your Account



'Looking forward to talking to FDA'

Fibrogen phase II pamrevlumab findings in IPF boost shares, partnering prospects

By Marie Powers
News Editor

Tuesday, August 8, 2017

Top-line findings from Fibrogen Inc.'s phase II study and two combination safety substudies of pamrevlumab (previously FG-3019) in patients with idiopathic pulmonary fibrosis (IPF) boosted the company's partnering prospects and propelled its shares (NASDAQ:FGEN) to a historic high.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription